

Prodromal Schedule of Activities (Years 6+)

Visit Number	R12	V13	R13	V14	R14	V15	R15	V16	R16	V17	R17	V18	R18	V19	R19	Annual (Y13+)	Remote	Transition Activities	Event Driven Modified Visit
Assessment ^a / Timepoint	66 mths	72 (Y6)	78 mths	84 (Y7)	90 mths	96 (Y8)	102 mths	108 (Y9)	114 mths	120 (Y10)	126 mths	132 (Y11)	138 mths	144 (Y12)	150 mths	156+ (Y13+)	162 mths+	---	---
Consent Activities																			
Documentation of Informed Consent	As Needed																		X
Continuing Consent	X		X		X		X		X		X		X		X		X		X
Research Information	As Needed																		
Decision Proxy	As Needed																		
Informed Consent Tracking	As Needed																		
General Activities																			
Demographics																			X
Family History																			X
Socio-Economics																			X
Program Assessment	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Vital Signs + Height and Weight		X		X		X		X		X		X		X		X			
Visit Status	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Screen Fail / Completion of Study																			As Needed
Neurological/Motor Assessments																			
Participant Motor Function Questionnaire		P		P		P		P		P		P		P		P			
Freezing and Falls		X		X		X		X		X		X		X		X			
Neurological Examination		I		I		I		I		I		I		I		I			
Initiation of Dopaminergic	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
MDS-UPDRS Part Ia	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Part Ib	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Part II	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Part III	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
MDS-UPDRS Part IV ^d	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
Hoehn and Yahr	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
Features of Parkinsonism	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
Other Clinical Features	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
Primary Research Diagnosis	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I	I		
Clinical Global Impression (CGI)		I		I		I		I		I		I		I		I			
Clinical Diagnosis	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Non-Motor Assessments																			
REM Sleep Behavior Disorder Screening		P		P		P		P		P		P		P		P			
Epworth Sleepiness Scale		P		P		P		P		P		P		P		P			
SCOPA-AUT		P		P		P		P		P		P		P		P			
Participant Global Impression (PGI)		P		P		P		P		P		P		P		P			
Neuro QoL		P		P		P		P		P		P		P		P			
Cognitive Assessments																			
Frontier Cognitive Assessment		X		X		X		X		X		X		X		X			
Clock Drawing*		X		X		X		X		X		X		X		X			
Lexical Fluency*		X		X		X		X		X		X		X		X			
Trail Making Test - Part B		X		X		X		X		X		X		X		X			
Attentional Blink Test		X		X		X		X		X		X		X		X			
Modified Semantic Fluency		X		X		X		X		X		X		X		X			
Letter Number Test		X		X		X		X		X		X		X		X			
Synonym Antonym Test		X		X		X		X		X		X		X		X			
Word Working Test (Adult)		X		X		X		X		X		X		X		X			
Word Working Test (Young Adult)		X		X		X		X		X		X		X		X			
Cognitive Change		P		P		P		P		P		P		P		P			
Cognitive Categorization		I		I		I		I		I		I		I		I			
Neuropsychological Assessments																			
MoCA		P		P		P		P		P		P		P		P			
Geriatric Depression Scale		P		P		P		P		P		P		P		P			
QUIP		P		P		P		P		P		P		P		P			
Clinical and Biological Samples																			
Research Biosamples (blood + urine)		X		X		X		X		X		X		X		X			
Lumbar puncture				X				X				X				X			
Skin biopsy ^f																			X
Safety and General Health																			
Adverse Events				X				X				X				X			
Adverse Event Reporting				X				X				X				X			
Concomitant Medication	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Participation in Other Studies	As Needed																		
Medication Log	As Needed																		
Surgery for PD Log	As Needed																		
Report of Pregnancy	As Needed																		

I = Investigator (or trained designee) completed assessment
P = Participant completed assessment
X = Investigator or Coordinator completed assessment (or as otherwise delegated)
a = rigidity and postural stability not assessed for Out of Clinic or Remote "R" visits; Part III and Hoehn & Yahr not done if phone/audio only
b = Transition Activities completed for all previously enrolled participants transitioning into new database at first visit only
c = Previously enrolled participants transitioning to new database may be asked to have skin biopsy. If not done at first visit, may be conducted at a subsequent in person visit.
d = Investigator or Coordinator may complete treatment and timing information.
e = If the participant is on levodopa, dopamine agonists, or has had DBS, the MDS-UPDRS Part III should be performed in the OFF and ON state.
f = Skin biopsy will be conducted at participating sites
H= see protocol section 11 for modification of visit schedule due to New Clinical Diagnosis, Need for PD Therapy or withdrawal from study
*Completed on paper source first, and then scores entered in to EDC.
**Window of +45 days either side of Target Visit Date
Adverse events collected only day of and 2-3 business days post LP and skin biopsy per protocol.
As needed assessments can be located under the Event Driven category in EDC